ReviewTherapeutic advances in medical oncology2022

Next-generation selective estrogen receptor degraders and other novel endocrine therapies for management of metastatic hormone receptor-positive breast cancer: current and emerging role.

Maxwell R Lloyd et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.